Syros Pharmaceuticals hits record low on QIAGEN deal termination and leadership changes

Syros Pharmaceuticals

18/11/2024 19:43

** Shares of Syros Pharmaceuticals  SYRS.O  down 24.1% at
$0.20, trading at an all-time low
    ** Co terminates its partnership with QIAGEN Manchester
Limited after a clinical trial for its blood cancer treatment,
tamibarotene, failed to meet its main goal
    ** Implements reduction in workforce by about 94%
    ** In connection with the workforce reduction, CEO Conley
Chee and CFO Jason Haas will be terminated without cause,
effective Nov. 22
    ** SYRS appoints Gerald Quirk as president and CEO
    ** Including session's gains, stock has fallen 97.4% YTD



 (Reporting by Nithyashree R B)
 ((NithyashreeRB@thomsonreuters.com))